why choose us

First received: September 23, 2022

Clinical Trial: Safety and Efficacy of Intravenous Cemiplimab Plus BNT116 Versus Cemiplimab Alone in Advanced Non-Small Cell Lung Cancer in Adult Participants With PD-L1 ? 50%

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced Non-Small Cell Lung Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (

Brief Summary: The study is researching an investigational drug, called BNT116, in combination with cemiplimab.BNT116 and cemiplimab will each be called a "study drug", and together be called "study drugs" in this form.The study is focused on patients who have advanced non-small cell lung cancer (NSCLC).The aims of the study are to see how safe and tolerable BNT116 is in combination with cemiplimab and to see how effective BNT116 in combination with cemiplimab is compared to cemiplimab by itself at treating…

Read more